Vitrolife ABOSTO:VITR -0.92%79 Days Payable is 53.65 as of Mar. 2026, which is 51% above its 10-year median of 35.59. GuruFocus rates OSTO:VITR with a GF Score™ of 79/100 and a GF Value™ of kr162.26 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 795 Medical Devices & Instruments companies, Vitrolife AB ranks worse than 70.44% on this metric.
The historical rank and industry rank for Vitrolife AB's Days Payable or its related term are showing as below:
OSTO:VITR'
s Days Payable Range Over the Past 10 Years
Min: 20.69 Med: 35.59 Max: 57.17
Current: 45.66
During the past 13 years, Vitrolife AB's highest Days Payable was 57.17. The lowest was 20.69. And the median was 35.59.
OSTO:VITR's Days Payable is ranked worse than 70.44% of 795
companies
in the Medical Devices & Instruments industry
Industry Median: 68.07
vs OSTO:VITR: 45.66
Vitrolife AB's Days Payable
increased
from Mar. 2025 (44.74) to Mar. 2026 (53.65).
It may suggest that Vitrolife ABdelayed paying its suppliers.
Vitrolife AB Days Payable Related Terms
Vitrolife AB Days Payable Historical Data
* Premium members only.
The historical data trend for Vitrolife AB's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:VITR vs ABT, SYK, MDT: Days Payable Comparison
For the Medical Devices subindustry, Vitrolife AB's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vitrolife AB Days Payable vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Vitrolife AB's Days Payable distribution charts can be found below:
* The bar in red indicates where Vitrolife AB's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Vitrolife AB's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vitrolife AB (OSTO:VITR) has a Days Payable of 53.65 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Vitrolife AB and its competitors. This is 51% above median its historical median of 35.59. Over the past decade, Vitrolife AB's Days Payable has ranged from 20.69 to 57.17. According to the industry distribution chart, Vitrolife AB ranks #560 out of 795 companies in the Medical Devices & Instruments industry, placing it in the top 70.4%.
Is Vitrolife AB's Days Payable too high?
Vitrolife AB's current Days Payable of 53.65 is 51% above median its 10-year median of 35.59. Over the past 10 years, this metric has ranged from a low of 20.69 to a high of 57.17. The Medical Devices & Instruments industry median Days Payable is 68.07. Vitrolife AB's value of 53.65 is 21.2% below this industry median. Based on the distribution chart, Vitrolife AB ranks #560 out of 795 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Vitrolife AB has a GF Score™ of 79/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Vitrolife AB's Days Payable compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Vitrolife AB ranks #560 out of 795 companies for Days Payable. This places Vitrolife AB in the lower half of its industry. The industry median Days Payable is 68.07. Vitrolife AB's value of 53.65 is 21.2% below this benchmark. Historically, Vitrolife AB's own Days Payable has ranged from 20.69 to 57.17 over the past decade. While the company's 10-year median is 35.59 vs. the industry median of 68.07, Vitrolife AB has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Devices & Instruments company?
The median Days Payable among Medical Devices & Instruments companies is 68.07, based on 795 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vitrolife AB's current Days Payable of 53.65 is 21.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Vitrolife AB and its competitors. For the Medical Devices & Instruments industry, the median Days Payable is 68.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vitrolife AB's current Days Payable is 53.65, which is 51% above median its own 10-year median of 35.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vitrolife AB stock overvalued right now?
Based on GuruFocus' analysis, Vitrolife AB (OSTO:VITR) is currently considered Possible Value Trap. The stock's GF Value™ is kr162.26, compared to a current price of kr91.10 — trading 43.9% below its estimated fair value. The current Days Payable is 53.65, which is 51% above median its 10-year median of 35.59 and 21.2% below the Medical Devices & Instruments industry median of 68.07. Vitrolife AB's overall GF Score™ is 79/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Vitrolife AB (OSTO:VITR), the current Days Payable is 53.65 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vitrolife AB (OSTO:VITR) Overvalued in 2026?
Based on GuruFocus' analysis, Vitrolife AB stock appears to be undervalued.
The current stock price of kr91.10 is trading 43.9% below its estimated GF Value™ of kr162.26.
GuruFocus considers Vitrolife AB to be Possible Value Trap.
Key valuation signals for OSTO:VITR:
Days Payable: 53.65 (51% above median its 10-year median of 35.59)
GF Value™: kr162.26 vs. price of kr91.10 (43.9% below fair value)
Industry Position: 21.2% below the Medical Devices & Instruments median (#560 of 795)
No single metric tells the full story. See the OSTO:VITR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vitrolife AB provides medical devices and genetic testing services intended for the reproductive-health market in the field of reproductive health. The company develops, manufactures, and distributes medical devices and provides genetic testing services for IVF clinics and their patients. Its mission is to support IVF clinics (in vitro fertilization) in enhancing their practice as well as the outcome of a patient's fertility treatment, thereby enabling patients to receive support to navigate the complexities of reproductive health through successful outcomes and patient satisfaction. The company has three geographical segments EMEA, Americas and APAC, out of which it derives maximum revenue from EMEA.
79GF Score
Get the complete analysis for OSTO:VITR
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:VITR has been successfully added to your 
